Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted October 9, 2007
Diabetes care in partnership with disease-associated complications regulates quality of life
Analysis of: Burden of diabetes care rivals disease complications | www.reuters.com
Author: GLG Member Program Contributor
The news reported in the Reuter on the 2nd October, 2007 has highlighted an important part of diabetes patient's quality of life. Contrary to popular beliefs about good care enhancing quality of life, the article reported the findings of a research of 701 adult diabetes patients fronm Chicago area...
Posted October 7, 2007
Diabetes.....
Analysis of: Burden of diabetes care rivals disease complications | www.reuters.com
Author: David Zimmerman, President/Owner Doctors of Pharmacy, Inc.
I know that Pfizer finally came out with the inhaled insulin after many years of hype. Unfortunately its launch and the product has been a flop, primarily because of the size if the inhaler. It is large and looks like a can of tennis balls. It is difficult for the patient to understand the dosing and...
Eric Gruff Posted October 5, 2007
Diabetes Patients Still Seek More Convenient Therapies. Pharma Isn't There Yet.
Analysis of: Burden of diabetes care rivals disease complications | www.reuters.com
Author: Eric Gruff, Principal E4 Consulting
A recent Chicago-area study has made it clear that diabetics view the daily-injection routine as being equally as onerous as many of the long-term complications from the uncontrolled disease. In addition to multiple daily injections, diabetic patients usually take several concommitant medications every...
Posted October 4, 2007
Quality of life versus quality of care
Analysis of: Burden of diabetes care rivals disease complications | www.reuters.com
Author: GLG Member Program Contributor
When patients elect to follow any physician advice, they are in effect demonstrating that they have weighed the costs of that advice (time, money, lifestyle modifications, etc) with the expected benefits.  All too often, however, patients do not understand or grossly underestimate the costs...
Posted October 4, 2007
Rimonabandt ( Accomplia) a viable and an effective tool in managenent of obesity
Analysis of: Sanofi aims to show there's still life in Acomplia | www.reuters.com
Author: GLG Member Program Contributor
Accomplia would be an effective new tool in management of obesity'A Dormant Volcano Waiting to Erupt' even amongst our youngsters,.Granted that it has adverseeffects i.e depression, suicidal ieation etc. However these disorders are frequently noted in Obese patients not using any meds it is also clear...
Posted October 3, 2007
Galvus Approved in Europe
Analysis of: Galvus(R) receives European approval as new treatment for type 2 diabetes with broad range of indications | www.pipelinereview.com
Author: GLG Member Program Contributor
Galvus is now approved for use in all 27 countries of the European Union, plus Norway, Iceland, Brazil, and Mexico.  It is the first in it's class to be approved for combination therapy with all three of the most commonly prescribed oral diabetic agents--metformin, sulfonyureas,...
Posted October 3, 2007
Galvus, Another DPP-4 Inhibitor on the Horizon (Healthcare, Novartis)
Analysis of: Galvus(R) receives European approval as new treatment for type 2 diabetes with broad range of indications | www.pipelinereview.com
Author: GLG Member Program Contributor
Galvus sounds very similar to Januvia, which is already approved and being used here in the United States with good results so far.  Because it targets the beta cell dysfunction and the glucagon pathway, it is very useful in the fight against diabetes, especially in combination therapy. ...
Posted October 3, 2007
Implications for use of Galvus in the U.S. after European approval is granted
Analysis of: Galvus(R) receives European approval as new treatment for type 2 diabetes with broad range of indications | www.pipelinereview.com
Author: GLG Member Program Contributor
The approval of Galvus in Europe increases the pressure on the FDA to approve its use in the United Status.
Glen McDaniel Posted September 28, 2007
Bariatric surgery may be a legitimate way to address diabetes
Analysis of: Bariatric surgery - possible treatment for type 2 diabetes mellitus | www.news-medical.net
Author: Glen McDaniel, President and Chief Executive Officer GM Global
Diabetes continues to be a global problem with hefty costs in dollars, death and disability.  Over the years treatment has not varied much-exercise, diet and use of insulin- and the problem continues to grow. If bariatric surgery shows amelioration of diabetes (if "cure" is too strong a worrd), ...
Posted September 27, 2007
You look Malvelous...who cares how you feel
Analysis of: Feel Pudgy? There’s a Shot for That | www.nytimes.com
Author: GLG Member Program Contributor
Beware of easy solutions for feeling pudgy, they may decrease fat deposits but will they change your self-image?  To add to the problem, regulation in this field is miniscule.  Will we have a repeat of breast implants, namely adding fat "in all the right places"?
Previous Page : 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Next161 to 170 of 373

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353